Results of 68Ga-PSMA PET/CT Imaging
| Result | Data |
| 68Ga-PSMA PET/CT-positive patients (n) | 601 (85.7%) |
| Median PSA level (ng/mL) | 12 (range, 0.003–4,337) |
| Median GS | 7 (range, 5–10) |
| 68Ga-PSMA PET/CT-negative patients (n) | 100 (14.3%) |
| Median PSA level (ng/mL) | 0.8 (range, 0.003–18.5) |
| Median GS | 8 (range, 5–10) |
| Metastatic sites of patients (n) | |
| Prostate/prostate bed | 400 (57%) |
| Seminal vesicle | 58 (8.2%) |
| Bladder/rectum | 29 (4.1%) |
| Bone | 278 (39.6%) |
| Oligometastatic (<4 lesions) | 108 (15.4%) |
| Multimetastatic (≥4 lesions) | 170 (24.2%) |
| Lymph nodes | 300 (42.7%) |
| Supradiaphragmatic | 91 (12.9%) |
| Abdominal | 128 (18.2%) |
| Pelvic | 272 (38.8%) |
| Lung | 36 (5.1%) |
| Liver | 24 (3.4%) |
| Other | 15 (2.1%) |
| Patient with bone metastasis (n) | 278 (39.6%) |
| Oligometastatic | 108 (15.4%) |
| Median PSA level (ng/mL) | 5.9 (range, 0.003–971.9) |
| Median GS | 7 (range, 6–10) |
| Multimetastatic | 170 (24.2%) |
| Median PSA level (ng/mL) | 25.8 (range, 0.003–4,337) |
| Median GS | 8 (range, 5–10) |
| Multimetastatic (without lower-limb metastasis) | 109 (15.5%) |
| Median PSA level (ng/mL) | 38.1 (range, 0.008–3,227) |
| Median GS | 8 (range, 6–10) |
| Multimetastatic (with lower- limb metastasis) | 61 (8.7%) |
| Median PSA level (ng/mL) | 78 (range, 1.16–4,337) |
| Median GS | 9 (range, 5–10) |
| Distribution of lower-limb metastasis (n) | |
| Distal femur | 54 |
| Tibia | 20 |
| Fibula | 24 |
| Calcaneus | 1 |
| Lower-limb metastasis (ratio) | |
| Symptom-positive patients | 70.9% (39/55) |
| Symptom-negative patients | 4% (22/546) |
| PSA ≤ 24 ng/mL | 23.4% |
| PSA > 24 ng/mL | 76.6% |